110836 ⎘
ssRNA viruses negative-sense; Details; Orthomyxoviridae; Influenzavirus B, i.e. influenza B virus Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
COMBINATION VACCINES AGAINST CORONAVIRUS INFECTION, INFLUENZA INFECTION, AND/OR RSV INFECTION
#2INFLUENZA VIRUS VACCINES
#3NUCLEIC ACID VACCINES
#4INFLUENZA VIRUS VACCINATION REGIMENS
#5INFLUENZA B VIRUS REPLICATION FOR VACCINE DEVELOPMENT
#6MRNA ENCODING INFLUENZA VIRUS-LIKE PARTICLE
#7INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE
#8INFLUENZA VIRUS VACCINES AND USES THEREOF
#9USE OF TOLL-LIKE RECEPTOR 2 (TLR-2) AGONIST FOR MODULATING HUMAN IMMUNE RESPONSE
#10POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST INFLUENZA VIRUS, AND IMPLEMENTATIONS THEREOF
#11RECOMBINANT SUBUNIT BASED UNIVERSAL INFLUENZA AND RESPIRATORY VIRUS VACCINES
#12RNA VACCINES AGAINST INFECTIOUS DISEASES
#13MULTIVALENT DISPLAY ON ENVELOPED PARTICLES WITH HUMAN OLIGOMERIZATION DOMAINS
#14SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES
#15NUCLEIC ACID CONSTRUCT AND USE THEREOF
#16NOVEL INFLUENZA ANTIGENS
#17VACCINATION OF IMMUNOCOMPROMISED SUBJECTS
#18VACCINATION OF IMMUNOCOMPROMISED SUBJECTS
#19IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF
#20SIGNAL SEQUENCES FOR NUCLEIC ACID VACCINES
#21INTRANASAL IMMUNOGENIC COMPOSITIONS
#22INFLUENZA VIRUS HEMAGGLUTININ PROTEINS AND USES THEREOF
#23MODIFIED INFLUENZA B HEMAGGLUTININ POLYPEPTIDES AND NUCLEIC ACIDS AND USES THEREOF
#24INFLUENZA VIRUS MUTANTS AND USES THEREFOR
#25Multicistronic Vaccine and Methods for Producing and Using the Same
#26PRODUCTION OF VIRUSES IN CELL CULTURE
#27SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES
#28NUCLEIC ACID VACCINES
#29NUCLEIC ACID VACCINES
#30NUCLEIC ACID VACCINES
#31Nucleic acid vaccines
#32Universal Influenza Vaccine and Methods of Use
#33RIBONUCLEOPROTEIN NANOCOMPLEX VACCINES AND USES THEREOF
#34VACCINATION OF IMMUNOCOMPROMISED SUBJECTS
#35Influenza virus hemagglutinin proteins and uses thereof
#36MULTIVALENT PAN-INFLUENZA VACCINE
#37CORONAVIRUS AND INFLUENZA COMPOSITIONS AND METHODS FOR USING THEM
#38RNA VACCINES AGAINST INFECTIOUS DISEASES
#39ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE
#40TEMPERATURE-CONTROLLABLE, SELF-REPLICATING RNA VACCINES FOR VIRAL DISEASES
#41INFLUENZA VIRUS NUCLEIC ACID LIPID PARTICLE VACCINE
#42INFLUENZA VACCINE COMPOSITIONS AND METHODS OF USING SAME
#43RESPIRATORY VIRUS COMBINATION VACCINES
#44INFLUENZA VACCINE FOR INTRANASAL ADMINISTRATION
#45INFLUENZA VACCINE
#46Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
#47INFLUENZA VACCINE COMPOSITIONS AND METHODS OF USING SAME
#48INFLUENZA B VIRUS MUTANTS AND USES THEREFOR
#49Influenza vaccines
#50AAV-MEDIATED EXPRESSION OF ANTI-INFLUENZA ANTIBODIES AND METHODS OF USE THEREOF
#51Removal of agglomerates
#52USE OF TOLL-LIKE RECEPTOR 2 (TLR-2) AGONIST FOR MODULATING HUMAN IMMUNE RESPONSE
#53ADJUVANT FORMULATIONS COMPRISING TLR4 AGONISTS AND METHODS OF USING THE SAME
#54Immunogenic compositions against influenza
#55Influenza virus mutants and uses therefor
#56Vaccine compositions having improved stability and immunogenicity
#57Methods of optimizing nucleotide sequences encoding engineered influenza proteins
#58Influenza virus hemagglutinin proteins and uses thereof
#59Engineered influenza antigenic polypeptides and immunogenic compositions thereof
#60INFLUENZA B VIRUS REPLICATION FOR VACCINE DEVELOPMENT
#61HIGH GROWTH INFLUENZA VIRUS
#62INFLUENZA VIRUS-LIKE PARTICLE PRODUCTION IN PLANTS
#63Proliferation method
#64Production of viruses in cell culture
#65Influenza vaccines
#66Vaccine compositions and methods of use
#67Removal of agglomerates
#68Use of toll-like receptor 2 (TLR-2) agonist for modulating human immune response
#69Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
#70Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
#71Methods of optimizing nucleotide sequences encoding engineered influenza proteins
#72Vaccines for human papilloma virus and methods for using the same
#73Influenza peptides and compositions
#74Cell-derived viral vaccines with low levels of residual cell DNA
#75FORMULATIONS FOR VIROSOMES
#76H7 avian influenza vaccine strain which differentiates infected from vaccinated animals, preparation method therefor, and application
#77Influenza vaccine
#78H9 avian influenza vaccine strain which differentiates infected from vaccinated animals, and preparation method therefor
#79Vaccination of immunocompromised subjects
#80Synthetic hemagglutinin as universal vaccine against infection by type B influenza viruses (IBV)
#81Influenza B virus mutants and uses therefor
#82H5 avian influenza vaccine strain which differentiates infected from vaccinated animals, preparation method therefor, and application
#83Generation of infectious influenza viruses from virus-like particles
#84Influenza virus-like particle production in plants
#85Immunogenic compositions against influenza
#86Headless hemagglutin influenza vaccine
#87Engineered influenza antigenic polypeptides and immunogenic compositions thereof
#88Mixture of non-digestible oligosaccharides for stimulating the immune system
#89Influenza virus reassortment
#90Methods and compositions for enhancing immune response to vaccination
#91Vaccine compositions
#92Influenza vaccines with reduced amounts of squalene
#93Vaccination of immunocompromised subjects
#94Vaccine compositions having improved stability and immunogenicity
#95MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES (MENSA) AND USES THEREOF
#96Influenza virus mutants and uses therefor
#97Immunomodulatory compositions and methods of use thereof
#98Compositions and methods to increase production
#99GENERIC ASSAYS FOR DETECTION OF INFLUENZA VIRUSES
#100Vaccine compositions and methods of use
#101Production of viruses in cell culture
#102Influenza virus hemagglutinin proteins and uses thereof
#103Immunogenic composition
#104REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS
#105NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES
#106Production of viruses in avian eggs
#107Influenza peptides and compositions
#108Vaccines for human papilloma virus and methods for using the same
#109Recombinant influenza virus-like particles (VLPS) produced in transgenic plants
#110Influenza vaccines
#111Influenza virus vaccines and uses thereof
#112Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
#113NASAL INFLUENZA VACCINE COMPOSITION
#114Method for producing RNA molecule compositions
#115Decreasing potential iatrogenic risks associated with influenza vaccines
#116METHOD FOR CULTURING MDCK CELLS
#117Influenza virus mutants and uses therefor
#118Influenza vaccine
#119NUCLEIC ACID VACCINES
#120COMPUTATIONALLY OPTIMIZED BROADLY REACTIVE ANTIGENS FOR INFLUENZA
#121Nucleic acid vaccines
#122INFLUENZA NUCLEIC ACID MOLECULES AND VACCINES MADE THEREFROM
#123Production of viruses in avian eggs
#124Production of viruses in cell culture
#125Oil-in-water emulsion influenza vaccine
#126INFLUENZA VIRUS VACCINES AND USES THEREOF
#127Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
#128Microneedle compositions and methods of using same
#129Engineered influenza antigenic polypeptides and immunogenic compositions thereof
#130Reverse genetics systems
#131Influenza vaccines
#132ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE
#133Methods and compositions for enhancing immune response to vaccination
#134Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#135Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#136Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity.
#137Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#138Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
#139Peptide sequences and compositions
#140Methods of use of influenza vaccine for prevention of pneumonia
#141Methods of optimizing nucleotide sequences encoding engineered influenza proteins
#142AAV-mediated expression of anti-influenza antibodies and methods of use thereof
#143Non-gelatin vaccine protectant composition and live attenuated influenza vaccine
#144Peptide sequences and compositions
#145Vaccine compositions having improved stability and immunogenicity
#146Immunogenic composition
#147Influenza virus vaccination regimens
#148FORMULATION OF SUGAR SOLUTIONS FOR CONTINUOUS ULTRACENTRIFUGATION FOR VIRUS PURIFICATION
#149NOVEL SYNTHETIC ANTICANCER, ANTIFUNGAL, AND ANTIBACTERIAL VACCINES
#150VACCINATION OF IMMUNOCOMPROMISED SUBJECTS
#151Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
#152Influenza B virus replication for vaccine development
#153Oil-in-water emulsion influenza vaccine
#154Mixture of non-digestible oligosaccharides for stimulating the immune system
#155Adjuvanted Influenza Vaccines for Pediatric Use
#156Vaccine compositions having improved stability and immunogenicity
#157Microneedle compositions and methods of using same
#158Vaccine containing virus-like particles
#159Nucleic acid molecules encoding ferritin-hemagglutinin fusion proteins
#160Compositions of multimeric-multiepitope influenza polypeptides and their production
#161Polyvalent influenza virus-like particles (VLPS) and use as vaccines
#162Soluble needle arrays for delivery of influenza vaccines
#163Synthetic derivatives of MPL and uses thereof
#164Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
#165Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
#166Vaccine compositions comprising a saponin adjuvant
#167Immunogenic composition
#168COMPOSITIONS AND METHODS TO INCREASE PRODUCTION
#169Peptide sequences and compositions
#170Inactivated whole virion vaccine-containing microneedle array preparation and method for administering the same
#171Identification and attenuation of the immunosuppressive domains in fusion proteins of enveloped RNA viruses
#172Influenza virus vaccines and uses thereof
#173Live-attenuated virus and methods of production and use
#174Nucleic acid vaccines
#175Nucleic acid vaccines
#176FORMULATIONS FOR VIROSOMES
#177Immunomodulatory compositions and methods of use thereof
#178PROCESS FOR PREPARING INFLUENZA VACCINES
#179ATTENUATED NEGATIVE STRAND VIRUSES WITH ALTERED INTERFERON ANTAGONIST ACTIVITY FOR USE AS VACCINES AND PHARMACEUTICALS
#180GENERIC ASSAYS FOR DETECTION OF INFLUENZA VIRUSES
#181Influenza vaccine
#182Decreasing potential iatrogenic risks associated with influenza vaccines
#183Influenza vaccines with reduced amounts of squalene
#184Process for stabilizing an adjuvant containing vaccine composition
#185Influenza virus mutants and uses therefor
#186Influenza virus mutants and uses therefor
#187Use of EGFR pathway inhibitors to increase immune responses to antigens
#188Thermally stable vaccine formulations and microneedles
#189Method for preparing virosomes
#190Mucosal vaccine composition
#191Intranasal vaccination dosage regimen
#192Method for preparing virosomes
#193Influenza virus-like particle production in plants
#194Influenza virus reassortment
#195MDCK-derived cell strain suspension-cultured in protein-free medium and method for proliferating virus using cell strain
#196Media elaborated with newly synthesized antibodies (MENSA) and uses thereof
#197Nanoemulsion influenza vaccine
#198Formulation of sugar solutions for continuous ultracentrifugation for virus purification
#199METHODS OF PRODUCING INFLUENZA VACCINE COMPOSITIONS
#200Influenza virus reassortment
#201Vaccines for human papilloma virus and methods for using the same
#202Influenza nucleic acid molecules and vaccines made therefrom
#203Computationally optimized broadly reactive antigens for human and avian H5N1 influenza
#204Polyvalent fusion protein vaccine against influenza
#205Vaccine comprising an oil in water emulsion
#206Influenza virus reassortment
#207Influenza virus vaccines and uses thereof
#208Influenza vaccination
#209Influenza virus vaccines and uses thereof
#210Influenza vaccines
#211MDCK-derived cell lines adapted to serum-free culture and suspension culture and method for preparing vaccine virus using the cells
#212Flagellin Fusion Proteins
#213IC31 nanoparticles
#214Production of infectious influenza viruses
#215Recombinant influenza vectors with tandem transcription units
#216Flagellin fusion proteins
#217Deletion mutants of flagellin and methods of use
#218FUSION PROTEINS AND METHODS OF USE
#219Increasing virus-like particle yield in plants
#220Deletion mutants of flagellin and methods of use
#221Virus-like particles comprising a matrix protein from a plant enveloped virus and uses thereof
#222Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
#223Adjuvant formulations comprising TLR4 agonists and methods of using the same
#224Compositions and methods for treating influenza
#225Multi-strain-reactive antibodies for therapy and diagnosis of influenza
#226Adjuvanted influenza virus compositions
#227Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
#228Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses
#229Influenza virus vaccines and uses thereof
#230Use of GK-1 peptide expressed on M13 filamentous phage as pharmaceutical ingredient to enhance the efficiency of the immune response induced by vaccine or pathogen antigens
#231Influenza hemagglutinin protein-based vaccines
#232Immune methods against influenza viruses and combinatorial vaccines thereof
#233Multimeric multiepitope influenza vaccines
#234Fusion proteins and methods of use
#235Vaccine composition with aluminium hydroxide nanoparticles
#236Nanoparticles, process for preparation and use thereof as carrier for amphipatic and hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
#237Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
#238Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
#239Influenza B viruses having alterations in the hemagglutinin polypeptide
#240Process for stabilizing an adjuvant containing vaccine composition
#241Multi plasmid system for the production of influenza virus
#242Influenza virus mutants and uses therefor
#243Batches of recombinant adenovirus with altered terminal ends
#244Fusion proteins and methods of use
#245Soluble needle arrays for delivery of influenza vaccines
#246Adjuvanted influenza vaccines for pediatric use
#247Peptide sequences and compositions
#248Methods of making hemagglutinin proteins
#249Methods of producing influenza vaccine compositions
#250Computationally optimized broadly reactive antigens for influenza
#251Recombinant modified vaccinia virus Ankara influenza vaccine
#252Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin
#253Methods of treatment with compositions that include hemagglutinin
#254Decreasing potential iatrogenic risks associated with influenza vaccines
#255Compositions and methods for treating influenza
#256Process for manufacturing vaccines
#257Methods and compositions for expressing negative-sense viral RNA in canine cells
#2581C31 nanoparticles
#259Reassortant influenza B viruses
#260Multi plasmid system for the production of influenza virus
#261Refrigerator-temperature stable influenza vaccine compositions
#262Reverse genetics systems
#263Methods for cultivating cells, propagating and purifying viruses
#264Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
#265COMBINATION VACCINES AGAINST RESPIRATORY TRACT DISEASES
#266Vaccine Having a Peptide Adjuvant for Eliciting a Specific Immune Response to Treat Viral Infection and Other Conditions
#267ADJUVANTED NANOPARTICULATE INFLUENZA VACCINE
#268VIRUS LIKE PARTICLES COMPRISING TARGET PROTEINS FUSED TO PLANT VIRAL COAT PROTEINS
#269Peptide sequences and compositions
#270Alphavirus replicon particles as immunological adjuvants
#271PROCESS FOR PREPARING AN INFLUENZA SEED VIRUS FOR VACCINE MANUFACTURE
#272GENERIC ASSAY FOR DETECTION OF INFLUENZA VIRUSES
#273Transcutaneous immunization without heterologous adjuvant
#274Multi plasmids system for the production of influenza virus
#275Chimeric influenza virus-like particles comprising hemagglutinin
#276Reverse genetics using non-endogenous pol I promoters
#277MIXTURE OF NON-DIGESTIBLE OLIGOSACCHARIDES FOR STIMULATING THE IMMUNE SYSTEM
#278Vaccine
#279Live attenuated influenza virus vaccines comprising microRNA response elements
#280Influenza hemagglutinin and neuraminidase variants
#281INFLUENZA VACCINES WITH INCREASED AMOUNTS OF H3 ANTIGEN
#282Influenza vaccines with reduced amounts of squalene
#283Influenza vaccine
#284METHOD FOR PRODUCING VIRUS FROM CELL CULTURE INVOLVING HOMOGENIZATION
#285COMPOSITIONS AND METHODS FOR VACCINE AND VIRUS PRODUCTION
#286Methods for one-dose intradermal delivery for non-live trivalent influenza vaccine
#287Decreasing potential iatrogenic risks associated with influenza vaccines
#288INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS
#289Influenza Vaccines, Antigens, Compositions, and Methods
#290KITS FOR ONE-DOSE INTRADERMAL DELIVERY FOR NON-LIVE TRIVALENT INFLUENZA VACCINE
#291ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE
#292Preservation of bioactive materials by freeze dried foam
#293Vaccines for Pandemic Influenza
#294Recombinant influenza vectors with tandem transcription units
#295MULTIVALENT ADJUVANTED INFLUENZA VIRUS COMPOSITIONS
#296Influenza vaccine
#297Vaccine composition for use against influenza
#298Influenza hemagglutinin and neuraminidase variants
#299Vaccine compositions comprising a saponin adjuvant
#300DNA vaccines, uses for unprocessed rolling circle amplification product and methods for making the same